Immune checkpoints represent a promising breakthrough in targeted therapy and prognosis of myelodysplastic syndrome
Myelodysplastic syndrome (MDS) is a hematological malignancy of undetermined etiology, possibly linked to chromosomal structural alterations, genetic mutations, presentation and carcinogenicity of variant antigens on cell surface, and the generation of pro-inflammatory microenvironment in the bone m...
Main Authors: | Xinyu Guo, Shunjie Yu, Xiaotong Ren, Lijuan Li |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2023-09-01
|
Series: | Heliyon |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2405844023064307 |
Similar Items
-
Autoimmune syndromes presenting as a paraneoplastic manifestation of myelodysplastic syndromes: clinical features, course, treatment and outcome
by: Bradley T. Williamson, et al.
Published: (2016-05-01) -
Comparison and Implications of Mutational Profiles of Myelodysplastic Syndromes, Myeloproliferative Neoplasms, and Myelodysplastic/Myeloproliferative Neoplasms: A Meta-Analysis
by: Ziqi Wan, et al.
Published: (2020-10-01) -
Current State and Challenges in Development of Targeted Therapies in Myelodysplastic Syndromes (MDS)
by: Michele Stanchina, et al.
Published: (2021-04-01) -
Management of Adult Patients with Myelodysplastic Syndromes
by: Nicolas Bonadies
Published: (2017-08-01) -
Summary of animal models of myelodysplastic syndrome
by: Weisha Li, et al.
Published: (2021-03-01)